Reboxetine and Citalopram as an Adjunct Treatment to Second Generation Antipsychotics in the Treatment of Negative Symptoms of Schizophrenia

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01300364
Recruitment Status : Unknown
Verified November 2008 by Fundació Sant Joan de Déu.
Recruitment status was:  Recruiting
First Posted : February 21, 2011
Last Update Posted : February 21, 2011
Centro de Investigación Biomédica en Red de Salud Mental
Information provided by:
Fundació Sant Joan de Déu

Results Submitted - Not Posted on
Results information has been submitted to by the sponsor or investigator, but is not yet publicly available (or "posted") on The submitted information may not be available if it is pending Quality Control (QC) Review by the National Library of Medicine (NLM) or if issues identified during QC review are being addressed or corrected by the sponsor or investigator. NLM's limited QC review assesses for apparent errors, deficiencies, or inconsistencies. NLM staff do not verify the scientific validity or relevance of the submitted information.
  Recruitment Status : Unknown
  Estimated Primary Completion Date : December 2011
  Study Completion Date : No date given

Submission Cycle Results Submitted to Results Returned after Quality Control Review
1 November 2, 2012
(Canceled - Date Unknown)
November 15, 2012
(Canceled - Date Unknown)
November 19, 2012
December 17, 2012
2 April 17, 2013
May 23, 2013
3 May 27, 2013
(Canceled - Date Unknown)
May 29, 2013
July 3, 2013